{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:01:53Z","timestamp":1649005313620},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00120-008-1874-3","type":"journal-article","created":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T01:30:21Z","timestamp":1222738221000},"page":"1357-1367","source":"Crossref","is-referenced-by-count":1,"title":["Systemische Therapie des metastasierten Nierenzellkarzinoms"],"prefix":"10.1007","volume":"47","author":[{"given":"M.","family":"Staehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Haseke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Zilinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Karl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,1]]},"reference":[{"key":"1874_CR1","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1200\/JCO.2007.13.3215","volume":"25","author":"Amato","year":"2007","unstructured":"Amato RJ, Harris P, Dalton M et al. (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25: 5026","journal-title":"J Clin Oncol"},{"key":"1874_CR2","first-page":"Abstr","volume":"26","author":"Amato","year":"2008","unstructured":"Amato RJ, Jac J, Harris P et al. (2008) A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol Suppl 26: Abstr 5122","journal-title":"J Clin Oncol Suppl"},{"key":"1874_CR3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2004.06.155","volume":"22","author":"Atzpodien","year":"2004","unstructured":"Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188\u20131194","journal-title":"J Clin Oncol"},{"key":"1874_CR4","first-page":"Abstr","volume":"26","author":"Bajetta","year":"2008","unstructured":"Bajetta E, Ravaud A, Bracarda S et al. (2008) Efficacy and safety of first-line bevacizumab (BEV) plus interferon-\u03b12a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol Suppl 26: Abstr 5095","journal-title":"J Clin Oncol Suppl"},{"key":"1874_CR5","first-page":"Abstr","volume":"26","author":"Bukowski","year":"2008","unstructured":"Bukowski RM, Stadler WM, Figlin RA et al. (2008) Safety and efficacy of sorafenib in elderly patients: a subset analysis from the advanced renal cell carcinoma sorafenib (ARCCS) expanded access program in North America. J Clin Oncol Suppl 26: Abstr 5045","journal-title":"J Clin Oncol Suppl"},{"key":"1874_CR6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125\u2013134","journal-title":"N Engl J Med"},{"key":"1874_CR7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103\u20132111","journal-title":"Lancet"},{"key":"1874_CR8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"Flanigan","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655\u20131659","journal-title":"N Engl J Med"},{"key":"1874_CR9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","volume":"171","author":"Flanigan","year":"2004","unstructured":"Flanigan RC, Mickisch G, Sylvester R et al. (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071\u20131076","journal-title":"J Urol"},{"key":"1874_CR10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271\u20132281","journal-title":"N Engl J Med"},{"key":"1874_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"Mcdermott","year":"2005","unstructured":"Mcdermott DF, Regan MM, Clark JI et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133\u2013141","journal-title":"J Clin Oncol"},{"key":"1874_CR12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, Van Poppel H et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966\u2013970","journal-title":"Lancet"},{"key":"1874_CR13","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530\u20132540","journal-title":"J Clin Oncol"},{"key":"1874_CR14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115\u2013124","journal-title":"N Engl J Med"},{"key":"1874_CR15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449\u2013456","journal-title":"Lancet"},{"key":"1874_CR16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eeus.2006.08.004","volume":"5","author":"Staehler","year":"2007","unstructured":"Staehler M, Haseke N, Sch\u00f6ppler G et al. (2007) Modern therapeutic approaches in metastatic renal cell carcinoma. Eur Urol EAU EBU Update Ser 5: 26\u201337","journal-title":"Eur Urol EAU EBU Update Ser"},{"key":"1874_CR17","first-page":"Abstr","volume":"26","author":"Szczylik","year":"2008","unstructured":"Szczylik C, Porta C, Bracarda S et al. (2008) Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26: Abstr 5124","journal-title":"J Clin Oncol"},{"key":"1874_CR18","first-page":"2957","volume":"62","author":"Turner","year":"2002","unstructured":"Turner KJ, Moore JW, Jones A et al. (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957\u20132961","journal-title":"Cancer Res"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1874-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-008-1874-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-008-1874-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:58:54Z","timestamp":1558609134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-008-1874-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1007\/s00120-008-1874-3","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}